{"title":"68Ga] Ga-FAPI-04 和 [18F] FDG 双示踪剂全身 PET/CT 和 PET/MR 成像的临床探索。","authors":"Yu Lin, Huaping Gao, Jiefu Zheng, Akram Al-Ibraheem, Pengcheng Hu, Hongcheng Shi","doi":"10.1053/j.semnuclmed.2024.09.009","DOIUrl":null,"url":null,"abstract":"<p><p>Fibroblast activation protein inhibitor (FAPI) and [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) provide complementary biological information, and FAPI/FDG dual-tracer imaging clinical application is increasing recently. However, optimal protocols for FAPI/FDG dual-tracer positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR) imaging are still under investigation. Due to its high sensitivity, total-body PET/CT allows for imaging with minimal tracer activity and supports the creation of new dual-tracer PET/CT imaging protocols. PET/MR, with its multiparametric MR imaging, provides additional biological information for diagnosis. Studies have investigated the clinical feasibility of low-activity PET/MR imaging, yielding promising results. As there are still few institutions in the world that have experience with the advances provided by the use of total-body PET/CT and equipped with a PET/MR scanner, we have discussed the clinical explorations to reduce radiation exposure and optimize workflows for [<sup>68</sup>Ga]Ga-FAPI-04 and [<sup>18</sup>F]FDG dual-tracer PET/CT and PET/MR imaging. The review also provides potential new clinical explorations of [<sup>68</sup>Ga]Ga-FAPI-04 and [<sup>18</sup>F]FDG dual-tracer total-body PET/CT and PET/MR imaging, including dual-tracer dual-low-activity imaging.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Explorations of [<sup>68</sup>Ga] Ga-FAPI-04 and [<sup>18</sup>F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging.\",\"authors\":\"Yu Lin, Huaping Gao, Jiefu Zheng, Akram Al-Ibraheem, Pengcheng Hu, Hongcheng Shi\",\"doi\":\"10.1053/j.semnuclmed.2024.09.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Fibroblast activation protein inhibitor (FAPI) and [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) provide complementary biological information, and FAPI/FDG dual-tracer imaging clinical application is increasing recently. However, optimal protocols for FAPI/FDG dual-tracer positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR) imaging are still under investigation. Due to its high sensitivity, total-body PET/CT allows for imaging with minimal tracer activity and supports the creation of new dual-tracer PET/CT imaging protocols. PET/MR, with its multiparametric MR imaging, provides additional biological information for diagnosis. Studies have investigated the clinical feasibility of low-activity PET/MR imaging, yielding promising results. As there are still few institutions in the world that have experience with the advances provided by the use of total-body PET/CT and equipped with a PET/MR scanner, we have discussed the clinical explorations to reduce radiation exposure and optimize workflows for [<sup>68</sup>Ga]Ga-FAPI-04 and [<sup>18</sup>F]FDG dual-tracer PET/CT and PET/MR imaging. The review also provides potential new clinical explorations of [<sup>68</sup>Ga]Ga-FAPI-04 and [<sup>18</sup>F]FDG dual-tracer total-body PET/CT and PET/MR imaging, including dual-tracer dual-low-activity imaging.</p>\",\"PeriodicalId\":21643,\"journal\":{\"name\":\"Seminars in nuclear medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-11-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1053/j.semnuclmed.2024.09.009\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.semnuclmed.2024.09.009","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Clinical Explorations of [68Ga] Ga-FAPI-04 and [18F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging.
Fibroblast activation protein inhibitor (FAPI) and [18F]fluorodeoxyglucose ([18F]FDG) provide complementary biological information, and FAPI/FDG dual-tracer imaging clinical application is increasing recently. However, optimal protocols for FAPI/FDG dual-tracer positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR) imaging are still under investigation. Due to its high sensitivity, total-body PET/CT allows for imaging with minimal tracer activity and supports the creation of new dual-tracer PET/CT imaging protocols. PET/MR, with its multiparametric MR imaging, provides additional biological information for diagnosis. Studies have investigated the clinical feasibility of low-activity PET/MR imaging, yielding promising results. As there are still few institutions in the world that have experience with the advances provided by the use of total-body PET/CT and equipped with a PET/MR scanner, we have discussed the clinical explorations to reduce radiation exposure and optimize workflows for [68Ga]Ga-FAPI-04 and [18F]FDG dual-tracer PET/CT and PET/MR imaging. The review also provides potential new clinical explorations of [68Ga]Ga-FAPI-04 and [18F]FDG dual-tracer total-body PET/CT and PET/MR imaging, including dual-tracer dual-low-activity imaging.
期刊介绍：
Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
